Study of Stem Cell and Exosome Therapy to Restore Fertility in Men and Women
Aged 20 to 50 With Testicular or Ovarian Failure
Evaluating Safety and Hormonal Recovery Over 12 Months
Led by Jumeirah American Clinic · Updated on 2025-04-10
60
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of stem cell or stem cell-derived exosome therapy for people with gonadal failure, which includes testicular failure, hypogonadism, ovarian insufficiency, and premature ovarian failure POF. The study focuses on adults aged 20 to 50 who have not responded well to usual treatments like hormone replacement therapy or assisted reproductive technologies. It aims to explore whether this regenerative treatment can restore hormone production and improve reproductive function, especially in a region where donor sperm and eggs are not allowed.
Participants will receive a single injection of adipose-derived stem cells or exosomes directly into their testes or ovaries under anesthesia. The stem cells or exosomes are prepared in a specialized lab and checked for safety and quality before administration. This open-label pilot study includes 60 participants, divided equally between men and women. Follow-up visits occur at 3, 6, 9, and 12 months after treatment to track changes in hormone levels, gonadal function, and reproductive capacity.
During the study, participants will have blood tests to measure hormones like testosterone and estradiol, imaging scans to assess gonadal tissue, and semen analysis for men. Researchers will monitor for any side effects or complications, including infections or immune reactions. The main outcome is the change in reproductive capacity after 12 months. Data collected will help guide future larger trials and contribute to developing new fertility treatments using regenerative medicine.
CONDITIONS
Brief Title
Fertility Enhancement Through Regenerative Treatment in Ovaries and Testes
Research Team
R
Ranjith Ramasamy, MD
S
Sheila May, RN
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Male patients diagnosed with testicular failure, hypogonadism, or azoospermia
Female patients diagnosed with premature ovarian failure or ovarian insufficiency
Suboptimal response to conventional treatments like hormone replacement therapy, testosterone therapy, or assisted reproductive technologies
General good health without significant contraindications to stem cell or exosome therapy
Willing and able to provide informed consent and comply with the study protocol
Patients seeking further treatment for gonadal failure after evaluation
You will not qualify if you...
Severe comorbid conditions such as advanced cardiovascular disease, renal failure, or uncontrolled diabetes
Active cancer or history of cancer within the past 5 years
Active infections or systemic inflammatory diseases
History of testicular or ovarian surgery or trauma interfering with study outcomes
Use of anticoagulants or medications contraindicating stem cell or exosome therapy
Participation in another investigational treatment study within the past 6 months
Immune deficiencies or allergies related to the study treatment
Severe neurological disorders or cognitive impairment affecting consent or compliance
Women diagnosed with psychogenic ovarian dysfunction or infertility
Any condition that poses undue risk or interferes with the study as judged by the investigator
History of ovarian surgery or trauma affecting study outcomes
Other contraindications to stem cell or exosome therapy as determined by the study team
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 1 day
Participants receive a single intra-gonadal injection of adipose-derived stem cells or stem cell-derived exosomes into the ovaries or testes under anesthesia.
1 treatment visit (in-person)
Follow-Up Monitoring
Duration - 12 months
Participants are monitored for safety and efficacy outcomes including hormonal changes, gonadal tissue regeneration, reproductive function, and adverse events.
Visits at 3, 6, 9, and 12 months post-treatment (in-person)
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
52-Week Study with 24-Month Safety Extension Evaluating XYOSTED Testosterone Replacement in Males 12 to 17 Years Old with Hypogonadism
Study of Body, Functional, and Lifestyle Factors Linked to Testosterone Levels in Middle-Aged Men in Uzbekistan
One-Year Study of Testosterone Undecanoate Versus Placebo on Liver Fat in Overweight or Obese Men With Type 2 Diabetes or Prediabetes and Low Testosterone, Followed by Two-Year Open Phase on Heart and Metabolic Health
Assessment of Endothelial Dysfunction in Men with Erectile Dysfunction and Hormonal Therapy Using EndoPAT Device
Study of Estradiol and Testosterone Hormonal Subdermal Implants to Treat Menopausal Symptoms in Women with Natural, Premature, or Surgical Menopause
Study of Stem Cell and Exosome Therapy to Restore Fertility in Men and Women
Aged 20 to 50 With Testicular or Ovarian Failure
Evaluating Safety and Hormonal Recovery Over 12 Months
Studying Gene Variants Linked to Infertility in Adults with Non-Obstructive Azoospermia or Primary Ovarian Insufficiency
Testosterone Replacement Therapy Effects on Sexual and Cancer Outcomes After Radical Prostatectomy in Men with Low Testosterone
Stem Cell Therapy Using Insulin-Producing Mesenchymal Stem Cells for Youth with Type 1 Diabetes
AI-Assisted IntelliWell Platform to Detect Rare Sperm in Men with Non-Obstructive Azoospermia Undergoing Micro-TESE Surgery
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Improvement of Pregnancy Rate and Live Birth Rate in Poor Ovarian Responders by Intraovarian Administration of Autologous Menstrual Blood Derived- Mesenchymal Stromal Cells: Phase I/II Clinical Trial.